Hosted on MSN7m
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
YORK, Pa. — Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback